Geode Capital Management
PVLA

Geode Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Geode Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.2M Buy
276,164
+70,555
+34% +$8.56M ﹤0.01% 1719
2026
Q1 		$25.6M Buy
205,609
+26,617
+15% +$2.78M ﹤0.01% 1864
2025
Q4 		$18.7M Buy
178,992
+10,882
+6% +$928K ﹤0.01% 2044
2025
Q3 		$10.5M Sell
168,110
-5,876
-3% -$262K ﹤0.01% 2386
2025
Q2 		$3.92M Buy
173,986
+79,787
+85% +$1.87M ﹤0.01% 2854
2025
Q1 		$2.64M Buy
94,199
+79,929
+560% +$1.54M ﹤0.01% 2941
2024
Q4 		$171K Buy
14,270
+2,289
+19% +$36K ﹤0.01% 3953
2024
Q3 		$201K Buy
11,981
+1,358
+13% +$19.8K ﹤0.01% 3900
2024
Q2 		$105K Buy
10,623
+963
+10% +$10.9K ﹤0.01% 4125
2024
Q1 		$142K Buy
9,660
+142
+1% +$1.98K ﹤0.01% 4043
2023
Q4 		$139K Hold
9,518
– – ﹤0.01% 4072
2023
Q3 		$227K Buy
9,518
+1,225
+15% +$26.3K ﹤0.01% 3929
2023
Q2 		$110K Buy
8,293
+418
+5% +$25.3K ﹤0.01% 4298
2023
Q1 		$615K Hold
7,875
– – ﹤0.01% 3572
2022
Q4 		$655K Sell
7,875
-18
-0.2% -$1.45K ﹤0.01% 3547
2022
Q3 		$726K Buy
7,893
+12
+0.2% +$1.55K ﹤0.01% 3547
2022
Q2 		$1.18M Buy
7,881
+552
+8% +$101K ﹤0.01% 3350
2022
Q1 		$1.78M Sell
7,329
-780
-10% -$205K ﹤0.01% 3306
2021
Q4 		$2.45M Sell
8,109
-562
-6% -$180K ﹤0.01% 3273
2021
Q3 		$3.59M Buy
8,671
+1,516
+21% +$528K ﹤0.01% 3107
2021
Q2 		$2.19M Sell
7,155
-3,569
-33% -$783K ﹤0.01% 3243
2021
Q1 		$2.2M Buy
10,724
+59
+0.6% +$12.9K ﹤0.01% 3214
2020
Q4 		$2.13M Buy
10,665
+499
+5% +$104K ﹤0.01% 3045
2020
Q3 		$1.68M Buy
10,166
+891
+10% +$203K ﹤0.01% 2962
2020
Q2 		$2.3M Buy
9,275
+310
+3% +$72.5K ﹤0.01% 2766
2020
Q1 		$1.64M Buy
8,965
+1,141
+15% +$288K ﹤0.01% 2788
2019
Q4 		$2.26M Buy
7,824
+63
+0.8% +$17.5K ﹤0.01% 2934
2019
Q3 		$2.12M Buy
7,761
+4,428
+133% +$1.71M ﹤0.01% 2914
2019
Q2 		$1.25M Buy
3,333
+233
+8% +$69.5K ﹤0.01% 3165
2019
Q1 		$830K Sell
3,100
-522
-14% -$124K ﹤0.01% 3237
2018
Q4 		$770K Sell
3,622
-128
-3% -$39.7K ﹤0.01% 3216
2018
Q3 		$1.68M Buy
3,750
+160
+4% +$69.5K ﹤0.01% 2988
2018
Q2 		$1.46M Buy
3,590
+426
+13% +$203K ﹤0.01% 3023
2018
Q1 		$1.73M Buy
3,164
+665
+27% +$412K ﹤0.01% 2845
2017
Q4 		$1.51M Buy
2,499
+1,252
+100% +$582K ﹤0.01% 2911
2017
Q3 		$574K Buy
1,247
+248
+25% +$106K ﹤0.01% 3307
2017
Q2 		$404K Buy
999
+671
+205% +$196K ﹤0.01% 3429
2017
Q1 		$68K Buy
328
+167
+104% +$29.6K ﹤0.01% 3898
2016
Q4 		$18K Hold
161
– – ﹤0.01% 4009
2016
Q3 		$23K Hold
161
– – ﹤0.01% 3992
2016
Q2 		$20K Hold
161
– – ﹤0.01% 4029
2016
Q1 		$24K Hold
161
– – ﹤0.01% 4044
2015
Q4 		$29K Hold
161
– – ﹤0.01% 4069
2015
Q3 		$23K Buy
+161
New +$35.9K ﹤0.01% 4082

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Geode Capital Management's PVLA Position: Q2 2026 in Review

Geode Capital Management increased its Palvella Therapeutics (PVLA) stake by 34% in Q2 2026, buying an estimated $8.56M and bringing the position to 276,164 shares worth $42.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Geode Capital Management first reported a position in PVLA in Q3 2015 and has held it in 44 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Geode Capital Management held 276,164 shares of Palvella Therapeutics worth $42.2M as of Q2 2026.
  • Geode Capital Management bought 70,555 Palvella Therapeutics shares in Q2 2026, an estimated $8.56M.
  • Palvella Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1719 holding.
  • Geode Capital Management first reported a position in Palvella Therapeutics in Q3 2015 and has held it in 44 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.